Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | S1PR1 | P21453 | 7/20 | 0.35 |
| ▸ | SCN4A | P35499 | 2/20 | 0.35 |
| ▸ | GLA | P06280 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1175393 | 1.00 | TSHR (0.49) | TSHRALOX15KMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL3714866 | 0.92 | TSHR (0.47) | TSHRALOX15KMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL3714865 | 0.92 | TSHR (0.47) | TSHRALOX15KMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL773113 | 0.89 | TSHR (0.60) | TSHRALOX15KMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL1176040 | 0.80 | S1PR1 (0.54) | S1PR1S1PR3 | |
| SCHEMBL1176038 | 0.80 | S1PR1 (0.54) | S1PR1S1PR3 | |
| SCHEMBL28040009 | 0.77 | PGR (0.32) | ALDH1A1SCN4AMAPT | |
| SCHEMBL767863 | 0.72 | TSHR (0.65) | TSHRALOX15KMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL767862 | 0.72 | TSHR (0.65) | TSHRALOX15KMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL1176307 | 0.71 | ALDH1A1 (0.41) | TSHRKMT2ASMN1; SMN2ALDH1A1GLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2970236-B1 | PYRIDIN-4-YL DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2017-08-30 | — | — | EP | disclosed |
| US-9617250-B2 | Pyridin-4-yl derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2017-04-11 | — | — | US | disclosed |
| US-20160031866-A1 | PYRIDIN-4-YL DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2016-02-04 | — | — | US | disclosed |
| EP-2970236-A1 | PYRIDIN-4-YL DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2016-01-20 | — | — | EP | disclosed |
| WO-2014141171-A1 | PYRIDIN-4-YL DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2014-09-18 | — | — | WO | disclosed |
| US-8658675-B2 | Pyridin-4-yl derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2014-02-25 | — | — | US | disclosed |
| EP-2217594-B1 | NOVEL PYRIMIDINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2014-01-08 | — | — | EP | disclosed |
| EP-2454255-B1 | PYRIDIN-4-YL DERIVATIVES AS S1P1/EDG1 AGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2013-11-06 | — | — | EP | disclosed |
| US-8575200-B2 | Pyridin-2-yl derivatives as immunomodulating agents | ACTELION PHARMACEUTICALS LTD (CH) | 2013-11-05 | — | — | US | disclosed |
| EP-2252609-B1 | PYRIDIN-2-YL DERIVATIVES AS IMMUNOMODULATING AGENTS | ACTELION PHARMACEUTICALS LTD (CH) | 2013-04-17 | — | — | EP | disclosed |
| EP-2252609-A1 | PYRIDIN-2-YL DERIVATIVES AS IMMUNOMODULATING AGENTS | Actelion Pharmaceuticals Ltd. (CH) | 2010-11-24 | — | — | EP | disclosed |
| US-20100261702-A1 | THIOPHENE DERIVATIVES AS AGONISTS OF S1P1/EDG1 | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-10-14 | — | — | US | disclosed |
| US-20100234346-A1 | NOVEL PYRIMIDINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-09-16 | — | — | US | disclosed |
| EP-2222667-A2 | NOVEL THIOPHENE DERIVATIVES AS AGONISTS OF S1P1/EDG1 | Actelion Pharmaceuticals Ltd. (CH) | 2010-09-01 | — | — | EP | disclosed |
| EP-2217594-A2 | NOVEL PYRIMIDINE DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2010-08-18 | — | — | EP | disclosed |
| WO-2009109904-A1 | NOVEL AMINOMETHYL BENZENE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2009-09-11 | — | — | WO | disclosed |
| WO-2009109872-A1 | PYRIDIN-2-YL DERIVATIVES AS IMMUNOMODULATING AGENTS | ACTELION PHARMACEUTICALS LTD (CH) | 2009-09-11 | — | — | WO | disclosed |
| WO-2009109906-A1 | PYRIDINE COMPOUNDS | ACTELION PHARMACEUTICALS LTD (CH) | 2009-09-11 | — | — | WO | disclosed |
| WO-2009074950-A2 | THIOPHENE DERIVATIVES AS AGONISTS OF S1P1/EDG1 | ACTELION PHARMACEUTICALS LTD (CH) | 2009-06-18 | — | — | WO | disclosed |
| WO-2009057079-A2 | NOVEL PYRIMIDINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2009-05-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160031866-A1 | PYRIDIN-4-YL DERIVATIVES | CD4, IL2, CD47 | TSHR 1018/4885ALOX15 1074/4885KMT2A 3083/4885 |
| US-20100261702-A1 | THIOPHENE DERIVATIVES AS AGONISTS OF S1P1/EDG1 | S1PR1, S1PR3, S1PR5 | TSHR 580/4885ALOX15 547/4885KMT2A 3418/4885 |
| US-20100234346-A1 | NOVEL PYRIMIDINE DERIVATIVES | TYMP, TYMS, DPYD | TSHR 3634/4885ALOX15 2160/4885KMT2A 3011/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.